JCO precision oncology
Journal
Overview
publication venue for
-
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.
2024
-
Consideration of a Novel Surgical Approach in the Management of Gastric Adenocarcinoma and Proximal Polyposis Syndrome.
2024
-
Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation.
2022
-
Genomic Characterization of a RET Inhibitor-Resistant RET Fusion-Positive Lung Cancer by CSF Cell-Free DNA Hybrid Capture-Based Sequencing.
2020
-
Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.
2020
-
Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma.
2020
-
FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia.
2020
-
Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors.
2019
-
Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy.
2019
-
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
2019
-
Amplification of MYC and Its Enhancer Correlates With Genetic Ancestry in Lung Squamous Cell Carcinoma..
8.
2024
-
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification..
8.
2024
-
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer..
8.
2024
-
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome..
8.
2024
-
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study..
8.
2024
-
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics..
8.
2024
-
Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib..
8.
2024
-
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates..
8.
2024
-
Suggestions on Using Machine Learning Models and Cautions for Analyzing Censored Time-To-Event Outcomes..
8.
2024
-
NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor..
8.
2024
-
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer..
8.
2024
-
Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases..
8.
2024
-
Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma..
8.
2024
-
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies..
8.
2024
-
Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer..
7.
2023
-
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma..
7.
2023
-
Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors..
7.
2023
-
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer..
7.
2023
-
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab..
7.
2023
-
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis..
7.
2023
-
Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome..
7.
2023
-
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma..
7.
2023
-
Pathway Alterations in Stage II/III Primary Melanoma..
7.
2023
-
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group..
7.
2023
-
Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts..
6.
2022
-
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer..
6.
2022
-
Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma..
6.
2022
-
Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes..
6.
2022
-
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer..
6.
2022
-
Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance..
6.
2022
-
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma..
6.
2022
-
Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer..
6.
2022
-
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype..
6.
2022
-
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience..
6.
2022
-
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase..
6.
2022
-
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy..
6.
2022
-
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor..
5.
2021
-
Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing..
5.
2021
-
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence..
5.
2021
-
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer..
5.
2021
-
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer..
5.
2021
-
Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer..
5.
2021
-
Differential Impact of ALK Mutations in Neuroblastoma..
5.
2021
-
Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population..
5.
2021
-
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study..
5.
2021
-
Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome..
4.
2020
-
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs..
4.
2020
-
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer..
4.
2020
-
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer..
4.
2020
-
Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva..
4.
2020
-
Systematic Assessment of Tumor Purity and Its Clinical Implications..
4.
2020
-
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib..
4.
2020
-
BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer..
4.
2020
-
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy..
4.
2020
-
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials..
3.
2019
-
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer..
3.
2019
-
Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine..
3.
2019
-
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer..
3.
2019
-
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution..
3.
2019
-
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology..
3.
2019
-
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases..
3.
2019
-
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers..
3.
2019
-
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer..
3.
2019
-
Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer..
3.
2019
-
Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas..
3.
2019
-
Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High..
3.
2019
-
Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience..
3.
2019
-
Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma..
2018.
2018
-
Dramatic Response to Sequential BRAF Inhibition in BRAF V600E-Mutant Metastatic Lung Adenocarcinoma..
2.
2018
-
Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma..
2.
2018
-
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions..
2.
2018
-
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers..
2.
2018
-
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium..
2018.
2018
-
Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma..
2.
2018
-
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer..
2018.
2018
-
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion..
2018.
2018
-
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy..
2.
2018
-
Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability..
2018.
2018
-
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations..
2.
2018
-
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome..
2018.
2018
-
Specifying the True- and False-Positive Rates in Basket Trials..
1.
2017
-
DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas..
2017.
2017
-
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data..
2017.
2017
-
Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma..
2017.
2017
-
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma..
1.
2017
-
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models..
2017.
2017
-
Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board..
2017.
2017
-
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making..
2017.
2017
-
Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas..
2017.
2017
-
OncoKB: A Precision Oncology Knowledge Base..
2017.
2017
-
Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect.
2017
-
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy.
2018
-
Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of JCO Precision Oncology..
8.
2024
-
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.
2022
-
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
2022
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)